IN THE CLAIMS

The status of each claim is presented below.

1. (Twice Amended) A compound represented by formula (I):



(I)

wherein

X is hydrogen, halogen, trifluoromethyl, lower alkyl, unsubstituted or substituted phenyl, lower alkyl-thio, phenyl-lower alkyl-thio, lower alkyl-sulfonyl, or phenyl-lower alkyl-sulfonyl;

Y is hydrogen, hydroxyl, mercapto, lower alkoxy, lower alkyl-thio, halogen, lower alkyl, unsubstituted or substituted mononuclear aryl, or $-N(R^2)_2$;

R^1 is hydrogen or lower alkyl;

each R^2 is, independently, $-R^7$, $-(CH_2)_m-OR^8$, $-(CH_2)_m-NR^7R^{10}$, $-(CH_2)_n(CHOR^8)(CHOR^8)_n-CH_2OR^8$, $-(CH_2CH_2O)_m-R^8$, $-(CH_2CH_2O)_m-CH_2CH_2NR^7R^{10}$, $-(CH_2)_n-C(=O)NR^7R^{10}$, $-(CH_2)_n-Z_g-R^7$,$-(CH_2)_m-NR^{10}-CH_2(CHOR^8)(CHOR^8)_n-CH_2OR^8$, $-(CH_2)_n-CO_2R^7$, or



;

R^3 and R^4 are each, independently, hydrogen, a group represented by formula (A), lower alkyl, hydroxy lower alkyl, phenyl, phenyl-lower alkyl, (halophenyl)-lower alkyl, lower-(alkylphenylalkyl), lower alkoxyphenyl)-lower alkyl, naphthyl-lower alkyl, or pyridyl-lower alkyl, with the proviso that at least one of R^3 and R^4 is a group represented by formula (A):



(A)

wherein

each R^L is, independently, $-R^7$, $-(CH_2)_n-OR^8$, $-O-(CH_2)_m-OR^8$,

$-(CH_2)_n-NR^7R^{10}$, $-O-(CH_2)_m-NR^7R^{10}$, $-(CH_2)_n(CHOR^8)(CHOR^8)_n-CH_2OR^8$,

$-O-(CH_2)_m(CHOR^8)(CHOR^8)_n-CH_2OR^8$, $-(CH_2CH_2O)_m-R^8$,

$-O-(CH_2CH_2O)_m-R^8$, $-(CH_2CH_2O)_m-CH_2CH_2NR^7R^{10}$,

$-O-(CH_2CH_2O)_m-CH_2CH_2NR^7R^{10}$, $-(CH_2)_n-C(=O)NR^7R^{10}$,

$-O-(CH_2)_m-C(=O)NR^7R^{10}$,$-(CH_2)_n-(Z)_g-R^7$,$-O-(CH_2)_m-(Z)_g-R^7$,

$-(CH_2)_n-NR^{10}-CH_2(CHOR^8)(CHOR^8)_n-CH_2OR^8$,

$-O-(CH_2)_m-NR^{10}-CH_2(CHOR^8)(CHOR^8)_n-CH_2OR^8$,

$-(CH_2)_n-CO_2R^7$, $-O-(CH_2)_m-CO_2R^7$, $-OSO_3H$, -O-glucuronide, -O-glucose, or



;

each x is, independently, O, NR^7, C=O, CHOH, C=N-R^6, or represents a single bond;

each o is, independently, an integer from 0 to 10;

each p is, independently, an integer from 0 to 10;

with the proviso that (a) the sum of o and p in each contiguous chain is from 1 to 10 when x is O, NR^7, C=O, or C=N-R^6 or (b) that the sum of o and p in each contiguous chain is from 5 to 10 ~~4 to 10~~ when x represents a single bond;

each R^6 is, independently, -R^7, -OH, -OR^{11}, -$N(R^7)_2$, -$(CH_2)_m$-OR^8, -O-$(CH_2)_m$-OR^8, -$(CH_2)_n$-NR^7R^{10}, -O-$(CH_2)_m$-NR^7R^{10}, -$(CH_2)_n(CHOR^8)(CHOR^8)_n$-$CH_2OR^8$, -O-$(CH_2)_m(CHOR^8)(CHOR^8)_n$-$CH_2OR^8$, -$(CH_2CH_2O)_m$-$R^8$, -O-$(CH_2CH_2O)_m$-$R^8$, -$(CH_2CH_2O)_m$-$CH_2CH_2NR^7R^{10}$, -O-$(CH_2CH_2O)_m$-$CH_2CH_2NR^7R^{10}$, -$(CH_2)_n$-C(=O)$NR^7R^{10}$, -O-$(CH_2)_m$-C(=O)$NR^7R^{10}$,-$(CH_2)_n$-$(Z)_g$-$R^7$,-O-$(CH_2)_m$-$(Z)_g$-$R^7$, -$(CH_2)_n$-$NR^{10}$-$CH_2(CHOR^8)(CHOR^8)_n$-$CH_2OR^8$, -O-$(CH_2)_m$-$NR^{10}$-$CH_2(CHOR^8)(CHOR^8)_n$-$CH_2OR^8$, -$(CH_2)_n$-$CO_2R^7$, -O-$(CH_2)_m$-$CO_2R^7$, -$OSO_3H$, -O-glucuronide, -O-glucose,




wherein when two R^6 are -OR^{11} and are located adjacent to each other on a phenyl ring, the alkyl moieties of the two R^6 may be bonded together to form a methylenedioxy group;

each R^7 is, independently, hydrogen or lower alkyl;

each R^8 is, independently, hydrogen, lower alkyl, -C(=O)-R^{11}, glucuronide, 2-tetrahydropyranyl, or



;

each R^9 is, independently, -CO_2R^7, -$CON(R^7)_2$, -SO_2CH_3, or -C(=O)R^7;

each R^{10} is, independently, -H, -SO_2CH_3, -CO_2R^7, -C(=O)NR^7R^9,

-C(=O)R^7, or -CH_2-$(CHOH)_n$-CH_2OH;

each Z is, independently, CHOH, C(=O), $CHNR^7R^{10}$, $C=NR^{10}$, or NR^{10};

each R^{11} is, independently, lower alkyl;

each g is, independently, an integer from 1 to 6;

each m is, independently, an integer from 1 to 7;

each n is, independently, an integer from 0 to 7;

each Q is, independently, C-R^6;

or a pharmaceutically acceptable salt thereof, and

inclusive of all enantiomers, diastereomers, and racemic mixtures thereof.

2. (Previously Presented) The compound of Claim 1, wherein Y is -NH_2.

3. (Previously Presented) The compound of Claim 2, wherein R^2 is hydrogen.

4. (Previously Presented) The compound of Claim 3, wherein R^1 is hydrogen.

5. (Previously Presented) The compound of Claim 4, wherein X is chlorine.

6. (Previously Presented) The compound of Claim 5, wherein R^3 is hydrogen.

7. (Previously Presented) The compound of Claim 6, wherein each R^L is hydrogen.

8. (Previously Presented) The compound of Claim 7, wherein o is 4.

9. (Previously Presented) The compound of Claim 8, wherein p is 0.

10. (Previously Presented) The compound of Claim 9, wherein x represents a single bond.

11. (Previously Presented) The compound of Claim 10, wherein each R^6 is hydrogen.

12. Canceled.

13. Canceled.

14. (Previously Presented) The compound of Claim 1, wherein

X is halogen;

Y is $-N(R^7)_2$;

R^1 is hydrogen or C_1-C_3 alkyl; and

R^2 is $-R^7$, $-(CH_2)_m-OR^7$, or $-(CH_2)_n-CO_2R^7$;

R^3 is a group represented by formula (A); and

R^4 is hydrogen, a group represented by formula (A), or lower alkyl.

15. (Previously Presented) The compound of Claim 14, wherein

X is chloro or bromo;

Y is $-N(R^7)_2$;

R^2 is hydrogen or C_1-C_3 alkyl;

at most three R^6 are other than hydrogen as defined above; and

at most three R^L are other than hydrogen as defined above.

16. (Previously Presented) The compound of Claim 15, wherein Y is $-NH_2$.

17. (Previously Presented) The compound of Claim 16, wherein

R^4 is hydrogen;

at most one R^L is other than hydrogen as defined above; and

at most two R^6 are other than hydrogen as defined above.

18. (Previously Presented) The compound of Claim 17, wherein x is O, NR^7, C=O, CHOH, or C=N-R^6.

19. (Previously Presented) The compound of Claim 17, wherein x represents a single bond.

20. (Previously Presented) The compound of Claim 1, wherein x is O, NR^7, C=O, CHOH, or C=N-R^6.

21. (Previously Presented) The compound of Claim 1, wherein x represents a single bond.

22. (Previously Presented) The compound of Claim 1, wherein each R^6 is hydrogen.

23. (Previously Presented) The compound of Claim 1, wherein at most two R^6 are other than hydrogen as defined in Claim 1.

24. (Previously Presented) The compound of Claim 1, wherein one R^6 is other than hydrogen as defined in Claim 1.

25. (Previously Presented) The compound of Claim 1, wherein one R^6 is -OH.

26. (Previously Presented) The compound of Claim 1, wherein each R^L is hydrogen.

27. (Previously Presented) The compound of Claim 1, wherein at most two R^L are other than hydrogen as defined in Claim 1.

28. (Previously Presented) The compound of Claim 1, wherein one R^L is other than hydrogen as defined in Claim 1.

29. (Currently Amended) The compound of Claim 1, wherein x represents a single bond ~~and the sum of o and p is 4 to 6~~.

30. Canceled.

31. Canceled.

32. (Currently Amended) The compound of Claim 1 ~~31~~, which is in the form of a hydrochloride salt.

33. (Previously Presented) The compound of Claim 1, which is represented by the formula



34. (Previously Presented) The compound of Claim 33, which is in the form of a pharmaceutically acceptable salt.

35. (Previously Presented) The compound of Claim 34, which is in the form of a hydrochloride salt.

36-41. Canceled.

42. (Previously Presented) The compound of Claim 1, which is represented by the formula



43. (Previously Presented) The compound of Claim 42, which is in the form of a pharmaceutically acceptable salt.

44. (Previously Presented) The compound of Claim 43, which is in the form of a hydrochloride salt.

45-47. Canceled.

48. (Previously Presented) The compound of Claim 1, which is in the form of a pharmaceutically acceptable salt.

49. (Previously Presented) A pharmaceutical composition, comprising the compound of Claim 1 and a pharmaceutically acceptable carrier.

50. Canceled.

51. (Canceled).

52. (Previously Presented) A method of blocking sodium channels, comprising:

contacting sodium channels with an effective amount of the compound of Claim 1.

53-79. (Canceled).

80. (Previously Presented) A composition, comprising:

the compound of Claim 1; and

a P2Y2 inhibitor.

81. (Previously Presented) A composition, comprising:

the compound of Claim 1; and

a bronchodilator.

82. (New) The compound of Claim 1, which is in the form of a mesylate salt.

83. (New) A compound represented by formula (I):



(I)

wherein

X is hydrogen, halogen, trifluoromethyl, lower alkyl, unsubstituted or substituted phenyl, lower alkyl-thio, phenyl-lower alkyl-thio, lower alkyl-sulfonyl, or phenyl-lower alkyl-sulfonyl;

Y is hydrogen, hydroxyl, mercapto, lower alkoxy, lower alkyl-thio, halogen, lower alkyl, unsubstituted or substituted mononuclear aryl, or $-N(R^2)_2$;

R^1 is hydrogen or lower alkyl;

each R^2 is, independently, $-R^7$, $-(CH_2)_m-OR^8$, $-(CH_2)_m-NR^7R^{10}$, $-(CH_2)_n(CHOR^8)(CHOR^8)_n-CH_2OR^8$, $-(CH_2CH_2O)_m-R^8$, $-(CH_2CH_2O)_m-CH_2CH_2NR^7R^{10}$, $-(CH_2)_n-C(=O)NR^7R^{10}$, $-(CH_2)_n-Z_g-R^7$,$-(CH_2)_m-NR^{10}-CH_2(CHOR^8)(CHOR^8)_n-CH_2OR^8$, $-(CH_2)_n-CO_2R^7$, or



R^3 and R^4 are each, independently, hydrogen, a group represented by formula (A), lower alkyl, hydroxy lower alkyl, phenyl, phenyl-lower alkyl, (halophenyl)-lower alkyl, lower-(alkylphenylalkyl), lower alkoxyphenyl)-lower alkyl, naphthyl-lower alkyl, or pyridyl-lower alkyl, with the proviso that at least one of R^3 and R^4 is a group represented by formula (A):



(A)

wherein

each R^L is, independently, $-R^7$, $-(CH_2)_n-OR^8$, $-O-(CH_2)_m-OR^8$,

$-(CH_2)_n-NR^7R^{10}$, $-O-(CH_2)_m-NR^7R^{10}$, $-(CH_2)_n(CHOR^8)(CHOR^8)_n-CH_2OR^8$,

$-O-(CH_2)_m(CHOR^8)(CHOR^8)_n-CH_2OR^8$, $-(CH_2CH_2O)_m-R^8$,

$-O-(CH_2CH_2O)_m-R^8$, $-(CH_2CH_2O)_m-CH_2CH_2NR^7R^{10}$,

$-O-(CH_2CH_2O)_m-CH_2CH_2NR^7R^{10}$, $-(CH_2)_n-C(=O)NR^7R^{10}$,

$-O-(CH_2)_m-C(=O)NR^7R^{10}$,$-(CH_2)_n-(Z)_g-R^7$,$-O-(CH_2)_m-(Z)_g-R^7$,

$-(CH_2)_n-NR^{10}-CH_2(CHOR^8)(CHOR^8)_n-CH_2OR^8$,

$-O-(CH_2)_m-NR^{10}-CH_2(CHOR^8)(CHOR^8)_n-CH_2OR^8$,

$-(CH_2)_n-CO_2R^7$, $-O-(CH_2)_m-CO_2R^7$, $-OSO_3H$, -O-glucuronide, -O-glucose, or



each x is, independently, O, NR^7, C=O, CHOH, $C=N-R^6$, or represents a single bond;

each o is, independently, an integer from 0 to 10;

each p is, independently, an integer from 0 to 10;

with the proviso that (a) the sum of o and p in each contiguous chain is from 1 to 10 when x is O, NR^7, C=O, or $C=N-R^6$ or (b) that the sum of o and p in each contiguous chain is from 4 to 10 when x represents a single bond;

each R^6 is, independently, $-R^7$, -OH, $-OR^{11}$, $-N(R^7)_2$, $-(CH_2)_m-OR^8$, $-O-(CH_2)_m-OR^8$, $-(CH_2)_n-NR^7R^{10}$, $-O-(CH_2)_m-NR^7R^{10}$, $-(CH_2)_n(CHOR^8)(CHOR^8)_n-CH_2OR^8$, $-O-(CH_2)_m(CHOR^8)(CHOR^8)_n-CH_2OR^8$, $-(CH_2CH_2O)_m-R^8$, $-O-(CH_2CH_2O)_m-R^8$, $-(CH_2CH_2O)_m-CH_2CH_2NR^7R^{10}$, $-O-(CH_2CH_2O)_m-CH_2CH_2NR^7R^{10}$, $-(CH_2)_n-C(=O)NR^7R^{10}$, $-O-(CH_2)_m-C(=O)NR^7R^{10}$, $-(CH_2)_n-(Z)_g-R^7$, $-O-(CH_2)_m-(Z)_g-R^7$, $-(CH_2)_n-NR^{10}-CH_2(CHOR^8)(CHOR^8)_n-CH_2OR^8$, $-O-(CH_2)_m-NR^{10}-CH_2(CHOR^8)(CHOR^8)_n-CH_2OR^8$, $-(CH_2)_n-CO_2R^7$, $-O-(CH_2)_m-CO_2R^7$, $-OSO_3H$, -O-glucuronide, -O-glucose,



wherein when two R^6 are $-OR^{11}$ and are located adjacent to each other on a phenyl ring, the alkyl moieties of the two R^6 may be bonded together to form a methylenedioxy group;

with the proviso that at least one R^6 is other than hydrogen as defined above;

each R^7 is, independently, hydrogen or lower alkyl;

each R^8 is, independently, hydrogen, lower alkyl, $-C(=O)-R^{11}$, glucuronide, 2-tetrahydropyranyl, or



each R^9 is, independently, $-CO_2R^7$, $-CON(R^7)_2$, $-SO_2CH_3$, or $-C(=O)R^7$;

each R^{10} is, independently, -H, $-SO_2CH_3$, $-CO_2R^7$, $-C(=O)NR^7R^9$, $-C(=O)R^7$, or $-CH_2-(CHOH)_n-CH_2OH$;

each Z is, independently, CHOH, C(=O), $CHNR^7R^{10}$, $C=NR^{10}$, or NR^{10};

each R^{11} is, independently, lower alkyl;

each g is, independently, an integer from 1 to 6;

each m is, independently, an integer from 1 to 7;

each n is, independently, an integer from 0 to 7;

each Q is, independently, C-R^6;

or a pharmaceutically acceptable salt thereof, and

inclusive of all enantiomers, diastereomers, and racemic mixtures thereof.

84. (New) The compound of Claim 83, wherein Y is -NH_2.

85 (New) The compound of Claim 84, wherein R^2 is hydrogen.

86. (New) The compound of Claim 85, wherein R^1 is hydrogen.

87. (New) The compound of Claim 86, wherein X is chlorine.

88. (New) The compound of Claim 87, wherein R^3 is hydrogen.

89. (New) The compound of Claim 88, wherein each R^L is hydrogen.

90. (New) The compound of Claim 89, wherein o is 4.

91. (New) The compound of Claim 90, wherein p is 0.

92. (New) The compound of Claim 91, wherein x represents a single bond.

93. (New) The compound of Claim 83, wherein
X is halogen;

Y is $-N(R^7)_2$;

R^1 is hydrogen or C_1-C_3 alkyl; and

R^2 is $-R^7$, $-(CH_2)_m-OR^7$, or $-(CH_2)_n-CO_2R^7$;

R^3 is a group represented by formula (A); and

R^4 is hydrogen, a group represented by formula (A), or lower alkyl.

94. (New) The compound of Claim 93, wherein

X is chloro or bromo;

Y is $-N(R^7)_2$;

R^2 is hydrogen or C_1-C_3 alkyl;

at most three R^6 are other than hydrogen as defined above; and

at most three R^L are other than hydrogen as defined above.

95. (New) The compound of Claim 94, wherein Y is $-NH_2$.

96. (New) The compound of Claim 95, wherein

R^4 is hydrogen;

at most one R^L is other than hydrogen as defined above; and

at most two R^6 are other than hydrogen as defined above.

97. (New) The compound of Claim 96, wherein x is O, NR^7, C=O, CHOH, or C=N-R^6.

98. (New) The compound of Claim 96, wherein x represents a single bond.

99. (New) The compound of Claim 83, wherein x is O, NR^7, C=O, CHOH, or C=N-R^6.

100. (New) The compound of Claim 83, wherein x represents a single bond.

101. (New) The compound of Claim 83, wherein at most two R^6 are other than hydrogen as defined in Claim 1.

102. (New) The compound of Claim 83, wherein one R^6 is -OH.

103. (New) The compound of Claim 83, wherein each R^L is hydrogen.

104. (New) The compound of Claim 83, wherein at most two R^L are other than hydrogen as defined in Claim 83.

105. (New) The compound of Claim 83, wherein one R^L is other than hydrogen as defined in Claim 83.

106. (New) The compound of Claim 83, wherein x represents a single bond and the sum of o and p is 4 to 6.

107. (New) The compound of Claim 83, which is in the form of a hydrochloride salt.

108. (New) The compound of Claim 83, which is represented by the formula



109. (New) The compound of Claim 108, which is in the form of a pharmaceutically acceptable salt.

110. (New) The compound of Claim 109, which is in the form of a hydrochloride salt.

111. (New) The compound of Claim 83, which is represented by the formula



112. (New) The compound of Claim 111, which is in the form of a pharmaceutically acceptable salt.

113. (New) The compound of Claim 112, which is in the form of a hydrochloride salt.

114. (New) The compound of Claim 83, which is in the form of a pharmaceutically acceptable salt.

115. (New) A pharmaceutical composition, comprising the compound of Claim 83 and a pharmaceutically acceptable carrier.

116. (New) A compound represented by the formula



in the form of a pharmaceutically acceptable salt.

117. (New) The compound of Claim 116, which is in the form of a hydrochloride salt.

118. (New) The compound of Claim 116, which is in the form of a mesylate salt.

119. (New) A method of blocking sodium channels, comprising:

contacting sodium channels with an effective amount of the compound of any one of Claims 2-11, 14-29, 32-35, 42-44, 48, and 82-118.

120. (New) A method of blocking sodium channels, comprising:

contacting sodium channels with an effective amount of the composition of any one of Claims 49, 80, and 81.